Identifying the most relevant RNA carrier is critical for developing clinically applicable methods to isolate plasma components that enable reliable ALK fusion testing in NSCLC patients, minimizing analytical errors (false negatives/positives). The gene discussed is ALK; the disease is non-small cell lung carcinoma.